Tempus AI (NASDAQ:TEM) Upgraded to Hold at Wall Street Zen

Tempus AI (NASDAQ:TEM) was upgraded by Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Saturday.

Several other research analysts also recently commented on the stock. HC Wainwright reaffirmed a “buy” rating on shares of Tempus AI in a report on Friday. Jefferies Financial Group assumed coverage on shares of Tempus AI in a report on Monday, April 13th. They set an “underperform” rating and a $35.00 target price on the stock. Wolfe Research began coverage on Tempus AI in a research report on Tuesday, June 2nd. They set a “peer perform” rating on the stock. TD Cowen reaffirmed a “buy” rating on shares of Tempus AI in a report on Wednesday, July 15th. Finally, Freedom Capital raised Tempus AI to a “hold” rating in a report on Tuesday, June 30th. Nine research analysts have rated the stock with a Buy rating, five have given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $68.92.

Tempus AI Price Performance

NASDAQ TEM opened at $42.69 on Friday. The company has a market cap of $7.67 billion, a PE ratio of -24.82 and a beta of 3.46. Tempus AI has a 52 week low of $41.73 and a 52 week high of $104.32. The company has a quick ratio of 3.15, a current ratio of 3.31 and a debt-to-equity ratio of 2.96. The firm’s 50-day simple moving average is $51.65 and its two-hundred day simple moving average is $53.56.

Tempus AI (NASDAQ:TEM) last issued its earnings results on Tuesday, May 5th. The company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.08. The firm had revenue of $348.12 million during the quarter, compared to analyst estimates of $345.44 million. Tempus AI had a negative net margin of 22.20% and a negative return on equity of 53.83%. The company’s quarterly revenue was up 36.1% on a year-over-year basis. During the same quarter last year, the business earned ($0.24) earnings per share. Research analysts predict that Tempus AI will post -1.35 earnings per share for the current year.

Insider Transactions at Tempus AI

In other news, CEO Ryan Fukushima sold 33,284 shares of the firm’s stock in a transaction that occurred on Wednesday, July 8th. The shares were sold at an average price of $57.39, for a total value of $1,910,168.76. Following the completion of the transaction, the chief executive officer directly owned 167,763 shares in the company, valued at approximately $9,627,918.57. This trade represents a 16.56% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jennifer A. Doudna sold 2,673 shares of the business’s stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $55.00, for a total transaction of $147,015.00. Following the transaction, the director directly owned 25,942 shares of the company’s stock, valued at approximately $1,426,810. This represents a 9.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 616,043 shares of company stock valued at $31,748,593. Company insiders own 24.26% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. GC Wealth Management RIA LLC bought a new position in shares of Tempus AI in the fourth quarter worth $399,267,000. Voloridge Investment Management LLC boosted its stake in Tempus AI by 183.0% during the third quarter. Voloridge Investment Management LLC now owns 1,607,083 shares of the company’s stock valued at $129,708,000 after buying an additional 1,039,176 shares during the period. AQR Capital Management LLC bought a new stake in Tempus AI during the second quarter valued at $54,020,000. Sumitomo Mitsui Trust Group Inc. grew its position in Tempus AI by 23.4% during the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 4,326,313 shares of the company’s stock worth $195,636,000 after buying an additional 821,490 shares in the last quarter. Finally, Amova Asset Management Americas Inc. grew its position in Tempus AI by 23.4% during the first quarter. Amova Asset Management Americas Inc. now owns 4,326,313 shares of the company’s stock worth $195,549,000 after buying an additional 821,490 shares in the last quarter. 24.22% of the stock is owned by institutional investors.

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.